Indian Pharmaceuticals Export Industry

Contemporary scenario, critical analysis & future trends Sumeet Shekhar Neeraj ♣ India ● ● +91 78428 88751 ♣
MBA (IB) 2nd Year
GITAM School of International Business

Date: 05-10-2011

Accredited by NAAC with ‘A’ Grade Abstract India has emerged as a preferable manufacturing destination for global pharma majors namely Roche, EliLilly, Johnson & Johnson, Glaxo etc., the world leaders who have already ingrained themselves deep into the Indian market in line with Indian majors like Cipla, Dr. Reddys Labs, Ranbaxy and various others savouring high quality, cost effective production capabilities of India for their exports to the world market. The Indian Pharmaceutical industry has grown from a $333.33m turnover in 1980 to approximately $22.5bn by 2010 and the country now ranks 3rd in terms of volume of production (10% of global share) and 14th by value (1.5%). Exports ($12bn) of pharmaceuticals have consistently outstripped imports ($6.5bn). India currently exports drug intermediates, active pharmaceutical ingredients (APIs), finished dosage formulations, bio–pharmaceuticals and clinical services. The sooner India manages to close the infrastructure gap (major central infrastructure projects mainly roads, ports, airports and power plants, 55% delayed, 2009 data), the financial gap (huge costs and time for international approvals and registration processes) the faster the growth will be in Indian pharmaceutical industry (Economic Survey of India 2010). The focus markets of Indian pharmaceutical exports industry largely needs R&D spending, financial aids, policy in action, mergers and acquisitions to be improved, reviewed and critically identified, modulated and studied respectively to grab the largest pie of the export market plethora for the future growth of the industry. INTRODUCTION India's pharmaceutical sector has seen unprecedented changes in the past decades ensuing for a remarkable growth in its exports (pharmaceutical exports occupy a share of 4.4% to 5.2% of India's total exportsi over the last 6 years) and exports grew at a CAGR of around 22% in the 6 year period of 2004-05 to 2009-10. Indian Pharma Exports ($bn) & % Share of Total Exports
12.00 10.00 8.00 6.00 4.00 2.00 0.00 Pharma Exp ($Bn) Share of total Exp

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

The industry in the country now ranks 3rd in terms of volume of production (10 per cent of global share) and 14th by value. Exports ($10.3bn) of pharmaceuticals have consistently outstripped imports ($6.5bn)ii. India‟s growth story in itself vindicates its potential, it had a $333.33m turnover in 1980 to around $22.30 bn by 2010-11 and a number of the country's largest pharmaceutical companies are attaining global-player status (viz. Cipla, Ranbaxy, Dr. Reddy‟s Labs, Lupin, Sun Pharma, Cadila etc.) as existing markets expand (the less regulated markets/LRMs viz. Thailand, Cambodia, Malaysia, Pakistan, Vietnam, Ukraine, Belarus and Moldova, with other importing LRMs in Azerbaijan and Kyrgyzstan), and new ones open up (Iran, Saudi Arabia, China, Georgia , South Africa etc.), for high quality, affordable generic drugs in the highly lucrative markets. Approximately $123bn of generic products is at risk (subject to patent renewal approvals by regulators) of losing patents by 2012. Even at a conservative estimate of 15% opportunity this translates into $18.4bn opportunity for Indiaiii. However the figures need to be appropriately deflated since Indian opportunity will lie in generics equivalent of branded drugs, which would be cheaper. Ageing populations of the US (plus the 2010 US Healthcare Reforms in action), China & European economies leading to the more and more expenditure on medicines and appreciation in the per capita consumption value of the drug products with cheaper rates, which is India forte (an astounding e.g.: In India, 100 tablets of Zinetac, a drug used in common peptic ulcers cost $2 while, in Chile, it‟s as much as $ 196). Generics business: The aforesaid companies have boosted their capacities, as demand continues to grow for the generics offered in the fields of antiretroviral therapy (Cipla), oncology (Cipla & Dr. Reddys), antibiotic therapy (Micro Labs, Aventis Pharma, Glaxo), insulins and vaccines (Biocon, Serum Institute of India) and other hormonal drugs; India manufactures more than 96 generic group drugs (including Para IV high risk high return products and Plain-Vanilla generics) offered to the global market. The Para IV‟s of Indian manufacturers have been a large revenue driver for some of the R&D based companies Viz. Ranbaxy, Dr. Reddys Labs, Hetero Drugs, Cipla etc. Para IV is one of the key strategies that have been believed to dominate thinking in the pharmaceutical industry; in order to grow fast; companies aggressively pursue investment in both new chemical entities and new products, which could successfully challenge existing patented drugs. This is a high risk-high reward business model; a strategy that has been found very useful is to file for a patent challenge under Para IV of the Hatch Waxman Act, 1984. Paragraph IV is an important aspect of the Hatch-Waxman Act- USA. Under this system, generic drug firms challenge pioneers drug patents in court. The claim is that that the generic version proposed to be launched by the manufacturer/claimant does not infringe the patent holder‟s version. If successful, the prevailing generic

Page 2 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

firm obtains a “180-day marketing exclusivity period” as the economic reward for its litigation efforts, and consumers benefit from earlier access to low-cost generic alternatives to the brand-name drug) Regulations: A 100% foreign direct investment through automatic route, liberalisation of rules related to foreign technology agreements as well as of the import regime, the introduction of Schedule-M, Schedule-T and revision of Schedule-Y (to permit conduct of phase II-IV clinical trials in India) of The Drugs and Cosmetics Act, 1940 had put upon a great impulse to the industry. There has been a recent tussle between industry leaders and heads of other institutions on reconsidering the industry to be regarded as sensitive one and reduce the automatic FDI route to 49% from prevailing 100%. The reconsideration is as of now been handed over to the Competition Commission of India (CCI)iv. PHARMEXCIL: The creation of PHARMEXCIL as well as a National Pharmaceuticals Policy with the objective of, among other things, has been rendering India as a preferred global destination for pharmaceutical R&D and manufacturing followed by exporting the drugs has proved successfulv. The recent creation of a separate Department of Pharmaceuticals is only a manifestation of the importance government of India has accorded to the sector. Markets & regulations: Currently India exports full basket of pharmaceutical products comprising intermediates, APIs, Finished Dosage Combinations (FDCs), biopharmaceuticals, vaccines, clinical services, etc., to various parts of the world. India is among the top 20 pharmaceutical exporters world-wide and with the largest number of US FDA inspected plants (119 plants), outside the USA. Various other agencies like MHRA (Medicines & Healthcare Regulatory Agency) UK, MCC (Medicines Control Council) South Africa, TGA (Therapeutic Goods Administration) Australia, HPB (Health Promotion Board) Canada have approved scores of plants in India5. Notably the global pharmaceutical markets are estimated at $773.1bn (2008) growing at 4.8% over the previous years. Broadly, Asia is the largest importing region from India with a share of 30% of India's pharmaceutical exports followed by Europe (24%) and North America (21%). During 2008-09 United States of America had been the top export destination with a share of approx. 18% in India's pharmaceutical exports valued at $1.55bn followed by Russia‟s valued at $0.33bn with a share of 3.84%, Germany ($0.31bn and 3.65%), Austria ($0.31bn and 3.58%) and UK ($0.27bn and 3.12%). In the year 2008-09, 58% of India's pharmaceutical exports comprised formulations valued at $5.03bn followed by Bulk Drugs (48%) valued at $3.6bn and herbals exports 3% valued at $251mvi. Pharma SMEs: According to the CII (Confederation of Indian Industries), there are around 80,000 smallscale units engaged in the areas of pharmaceutical formulations and bulk drugs. The present decade has opened up newer opportunities for the SMEs (Small- to Medium-Sized Enterprise) in the field of CRAMS (Contract Research and Manufacturing Services), Clinical trials etc. A number of them have received
Page 3 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

approvals from international regulatory authorities mentioned below for facilities and expertise; they can avail opportunities in CRAMs (e.g. Macleods Pharmaceuticals, Micro Labs, Alkem Ltd, Hetero Drugs, Ankur Drugs etc.). The product launches may help SMEs to secure manufacturing contracts and opportunities to supply Active Pharmaceutical Ingredients (APIs) and allied chemicals. The German Technical Cooperation has entered into a memorandum of understanding (MoU) with the Drugs & Pharmaceuticals Manufacturers Association (DPMA) of India to help pharma-SMEs that need interventions to brave the intense competition. India government has been making every attempt to support SMEs through several incentives. One such effort is the development of SMEs clusters in various parts of the country (e.g. Indore- SEZ, Baddi- Export Promotion Industrial Park- EPIP). Pricing & policy controls: The uncertainty in the pricing policy (governed by the National Pharmaceutical Pricing Committee and the Drug Price Control Order 1995) of drugs imposed by the Indian government at various levels of the industry on a number of essential drugs despite an increase in the price of raw material has taken a toll on the bottom lines of manufacturing companies, thereby hampering its R&D initiatives. A significant boost in certain critical areas such as manufacturing regulatory infrastructure (The Drugs and Cosmetics Act 1940 recent amendments in Schedule M, guiding the Good Manufacturing Practices have come in line with the standards of USFDA regulations) and new drug discovery programme (Schedule Y of the act), the improvised Indian Pharmacopoeial Compendia (in quasi equal standards to the United States Pharmacopoeia and the British Pharmacopoeia) can place India among the top pharmaceutical industries in the world. Bilaterals and International agreements: Post liberalization, the pharmaceutical export industry has had to reorganize itself to keep pace with the economic reforms that were taken on by India, the abolition of industrial licensing as well as the international export commitments mainly the bilaterals and agreements and/or pacts signed which testify a lot of decisive work and agreement on pharmaceutical tariff lines curb e.g. India-Ghana, India-Peru, India-Russia, India-Kenya, India-South Africa, India-Singapore, IndiaMongolia, India-Japan EPA, other comprehensive treaties and joint workings with almost all of the developing economies of the world for pharmaceuticals trade and businesses, now has begun exploring the greener pastures of countries like African countries (Nigeria, Kenya and various others etcvii.), India-Japan EPA (Economic Partnership Agreement, September 2010) would boost the industry as Japan is one of the global leaders in per capita drug consumption i.e. more than $412 followed by Germany- $222 and USA$191). India exported $1.38bn worth drugs & Pharmaceutical to Asia (approx. 19% of India‟s total pharma exports) and ASEAN countries accounted for $497.73m (approx. 36%)viii. Labour Costs: Skilled scientists/technicians/management personnel at affordable costs have kept India one of leading in the list, as studied by BLS (Bureau of Labour Statistics) Hourly labour compensation costs in
Page 4 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

India are among the lowest when compared with the 36 countries which are huge cost advantages (in 2005, India‟s average hourly compensation cost for all employees in manufacturing i.e. $0.91 was approximately 3.1% of the level seen in the United States i.e. $29.74) for the Western pharmaceutical companies of up to 60-70% aptly have made the country to be the choicest manufacturing & exporting destinations in the sector.
Comparison of Cost Advantage in India (%)ix Costs in the Western Countries (Taking) Production costs R&D Costs Clinical Trials Cost Source: Pharmexcil Research 100.0% 50.0% 12.5% 10.0%

Manufacturers’ Internal Infrastructure: The Indian skilled workforce and Western-equivalent research infrastructure owned by the Indian MNCs (Multi-National Companies) viz Lupin, Cipla, Ranbaxy, Dr. Reddys Labs etc. with well-equipped R&D labs with advanced imported technologies such as Nuclear magnetic resonance (NMR), advanced Chromatography (HPLCHigh Performance Liquid

Chromatography, Gas Chromatography etc.) based equipments, Infra-Red (IR) Spectroscopes etc., Clinical Research facilities and tie-ups with major clinical services providers viz. Clingene (Biocon), Quintiles, and various other Clinical Research Organizations (CROs) for their outsourced researches and clinical trials. Employment Costs Viz. Skilled scientists/technicians/management personnel at affordable costs have kept India one of leading in the list, as studied by BLS (Bureau of Labor Statistics) Hourly labour compensation costs in India are among the lowest when compared with the 36 countries which are huge cost advantages (in 2005, India‟s average hourly compensation cost for all employees in manufacturing i.e. $0.91 was approximately 3.1% of the level seen in the United States i.e. $29.74) for the Western pharmaceutical companies of up to 60-70% aptly have made the country to be the choicest manufacturing & exporting destinations in the sector. Scientific & Educational Institutions: The quality knowledge dissemination by institutions like Council of Scientific and Industrial Research (CSIR), National Research Development Corporation, Central Drug Standard Control Organization (CDSCO), Indian Council of Medical Research (ICMR), Indian Drug Manufacturers Association (IDMA) and various others, during the last few years there has been

phenomenal growth in the number of institutions imparting pharmaceutical education and combined admission capacity of the courses is about 61,000 seats scored through 500 plus colleges (teaching 2 years Diploma, 4 years Graduation, 2 years Post Graduation and 5 Plus years in PhD etc. regulated jointly by Pharmacy Council of India and All India Council of Technical Education). Expertise from institutions viz. CDRI (Central Drug Research Institute), IISc (Indian Institute of Science), NIPER (National Institute of Pharmaceutical Education and Research), NRDC (National Research Development Corporation) and various others, R&D capabilities, Science-Technology infrastructure and

Page 5 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

industry during the last five decades have also selectively developed to extraordinary levels as compared to that in most developing nations impelling greatly to the exports sector of the industry. India Pharma Patent Regime: The improved Intellectual Property protection after the introduction of TRIPS (Trade-Related Aspects of Intellectual Property Rights) and compulsory licensing (such licenses provide generics companies with restricted access to intellectual property in order to manufacture generic versions of patented medicines in good faith of the country‟s health) x, protected patent regime after the TRIPS (commitments taken by India under the WTO Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) forced a change in The Patents Act regime in 2005, bringing to the fore a major challenge for the country‟s pharmaceutical industry to comply with the TRIPS guidelines, the Product patent was reintroduced after 35 years again) provided a safe platform on which pharmaceutical exporters has helped them grow in India and also meet the need for increased production rather than relying on imports, which was once critical for the infant Indian national economy. The fact of the matter is that Indian manufacturers are still not able to encash the opportunity due to the lack of investments and government promotion in the Pharmaceuticals research (only a handful of government clinical and manufacturing research promotion and development institutions exist as mentioned above) and Public Private Partnership in the sector for promoting Orphan Drugs research and other similar projects as opportunities for the sector. Government’s Schemes & Initiatives: Reduced pro-manufacturing, CAPEX costs by duty exemption upto zero percent by EPCG scheme of Foreign Trade Policy) and expenditure to run cGMP compliance facilities and high quality documentation and process understanding is grossly being supported by the Government (DGFT & Deptt. Of Commerce) by the promotional policies viz. EPCG (Export Promotion Capital Goods), other duty drawback schemes (except DEPB which was discontinued from Oct-2011xi), MAI (Market Access Initiative, financial assistance is also provided for contesting litigation(s) in the foreign country concerning restrictions/anti-dumping duties etc. on particular product(s) of Indian origin), MDA (Marketing Development Assistance) DGFT (Directorate General of Foreign Trade) has been supportive to the exporters by leveraging the zero duty benefits and schemes of the Foreign Trade Policy 2009-2014, revised 2010. To promote pharmaceutical exports PHARMEXCIL-Hyderabad (works closely with the Department of Commerce and the Export Promotion Cell in the Department of Chemicals and Petrochemicals to undertake activities such as promoting exports, preparing country-profiles, assessing export potential across the countries and to have greater degree of interaction internationally), EXIM Bank (indulged in leveraging cheaper loans to the exporters and also does contract rating of importers), the creation of Pharma Parks, SEZs‟ (Special Economic Zones) and EPZs‟ (Export Processing Zones) dedicated to pharmaceutical manufacturers, export dedicated SEZs‟ e.g. Indore EPZ, Pune SEZ, Vizag Pharma City (largest) etc. have helped promoting the exports. In the Union Budget- 2011xii, the honourable Finance Minister (India) had
Page 6 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

proposed an increase in allocation towards healthcare from Rs. 19,354 Crore to Rs. 22,300 Crore & is it‟s expected that a significant part of this increased allocation will be utilized in improving healthcare infrastructure and delivery systems, in the country. Under section 10B, extension of sunset clause is expected to benefit the Export Oriented Units (EOUs) Tax Environment: In SEZs for the corporate taxes front, pharma units set up in SEZs enjoy 100% income tax exemption on export profits in the first five years of operation, 50% exemption for the next five years, and 50% exemption on the reinvested export profits in the following five years. Companies located in SEZ also benefit from various Indirect Tax benefits such as exemption from payment of Customs Duty; Excise Duty; Central Sales Tax and refund and exemption of Service Tax. The bottom line is that India Govt. and EPCs (Export Promotion Council) offer attractive tax benefits, reimbursements and reductions in customs duties which also help global manufacturers compete in the price-sensitive LRMs environment. Also in the Union Budget- 2011 tax incentives for the business of setting up and operating “Cold Chain” infrastructure, which is an integral part in the logistics for vaccines and many biotech products, has been provided. Key Challenges: R&D & Investments: Low investments by Indian drug makers (e.g. Ranbaxy maximum 12.6%) in innovative R&D compared to the Global players investing upto 20% (Eli Lilly maximum 20%) of their sales revenue continue to be a major weakness of Indian pharmaceutical exporters lacking capacities for filing more and more ANDA‟s and penetrating into the generic markets globally only and not in the Novel Drug Delivery Systems. The diffused nature of the Indian pharmaceutical industry has also been a concern that only about 20 to 30 companies (viz. Ranbaxy, Cipla, Dr Reddy's Labs, Lupin, Sun Pharmaceuticals, Nicholas Piramal, Zydus Cadila, Biocon, Glenmark Pharmaceuticals, Wockhardt Ltd, Torrent, Biocon, Matrix Labs etc.xiii are large enough to bear the transactions costs associated with sustained exports to and compliance with entry regulations of the developed markets which scores to crores. Their segment-wise generics account for 58 per cent of the total exports, active pharmaceutical ingredients (APIs) 40 per cent and

Ayurveda/herbal/neutraceuticals two per cent, according to industry reports. Non-Tariff Measures: The importing countries‟ regulations have been one of the bothering concerns, e.g. insistence on completing long process (e.g. average 3-4 years for a ANDA Stability Batch, for generics, till the Product‟s launch after approval, Novel Drug Delivery Systems call for average 10-16 years for a drug development till launch after NDA filing and approvals) for registration to the international (country specific) quality auditing agencies such as the USFDA (USA), MHRA (EU), TGA (Australia), EMEA (EU), MOH (Ministry of Health)-Thailand, China SFDA (State Food Drug Administration), GCC (Gulf Cooperation Council), MCC (South Africa), Canada FDA, MOH-Mexico, etc. and the mandates on allowing
Page 7 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

imports of only those drugs which are registered in some developed countries etc. The multiplicity of drug approval agencies in various countries has raised drug registration costs and site inspections costs. These regulatory agencies insist on pharmaceutical standards & quality procedures of their country, which often varies from country to country and ask for discrete quality audits to be conducted by their agencies independently. Indian manufacturers are prevented from bidding for government contracts as US permits bidders only from countries that are signatories to WTO Agreement on Government Procurement. The have to submit separate state level applications for marketing drugs in the United States as there is no nation-wide system of application even where FDA approval has been received Indian firms have often been accused of making counterfeit drugs by drug makers in the US and European markets unanimously cited to be allegations used to erect non-tariff measures for restricting competition from Indian companies who sell their low-cost drugs in the developed markets. As per a health ministry study, about 0.3% of drugs in with „Made in India‟ tag are spurious, while about 5% are counterfeit and not actually „Made in India‟. The Supply of spurious drugs, fake drugs with “Made in India” claims e.g. cases of such exports from China containing Indian Manufactured tags being caught in Nigeria. Data Exclusivity: In 2006, the USA placed India on the Special 301 Priority Watch List for not granting monopoly rights for clinical trial data (data exclusivity) that would give the patent holder five years of marketing exclusivity. Some pharmaceutical companies also pressured the Indian government. This occurred even though India‟s current law is TRIPS compliant. It allows the Indian drug regulatory authority to use the patent holder‟s clinical data to approve generic medicines rapidly. Implementing data exclusivity would reduce generic competition and devastate the ability of poor Indians to access affordable medicines There had been a number of protests against the recent (2010-2011) discussions on India-EU FTA with the data exclusivity clauses to be removed from the same have been successful and the strong lobbying by innovators have been carefully handled by the Ministry of External affairs and Ministry of Commerce, India in these regards to serve the cause/purpose of keeping maximum access of patients to the medicines they need mainly for endemics which are not completely curable as of now Viz. Cancer and AIDS medications across the nation and to keep a price control on such drugs. A study by Oxfam found that of 103 medicines registered and launched since 2001 that had no patent protection in Jordan, at least 79% had no competition from a generic equivalent as a consequence of data exclusivity. The study also found that prices of these medicines under data exclusivity were up to 800% higher than in neighbouring Egypt. India should not repeat others‟ mistakes, or the effect would be felt far beyond India‟s borders. The country is the source of the vast majority of drugs used to treat AIDS in developing countries. Affordable medicines produced in India have played a major part in reaching the more than five million people receiving HIV/AIDS treatment across the developing world today. India needs to stand strong and resist European demands in their FTAs.
Page 8 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

Monetary Resources: Majority of Indian SMEs lack the ability to compete with MNCs for New Drug Discovery, research and commercialization of molecules on a worldwide basis due to lack of monetary resources compared to the risk associated (research costs, patent litigations post-discovery, registration costs etc.). FUTURE TRENDS All in all Indian drug sales are expected to rise by an annual 8% to nearly $26.59bn between 2006 and 2015xiv. To be sure, this growth rate is higher than that seen for Germany (+5% p.a.) and the entire world (+6%). Nonetheless, India‟s share in world pharmaceutical sales will rise only marginally to a good 2%. It is likely that many of the Indian small companies will merge or disappear from the market altogether. The Commerce Ministry is mulling to formulate a policy on mergers and acquisitions by multinationals in the pharma sector e.g. Ranbaxy by Daichi Sankyo Japan, Dabur Pharma by Fresenius Kabi AG Germany, Piramal Healthcare by Abbott Labs USA. In the coming years, opening up of US generics market and antiretroviral therapy of AIDS market in Africa will boost exports since in the absence of a medical support. [Notably each day, 6,000 Africans die from AIDS. Each day, an additional 11,000 are infected.] The Pharma market in Thailand is fastest growing in Asia-Pacific region. It has a strong pharma Industry producing mostly generics. It depends on imports for patented drugs. The market is expected to be worth US $1 .82 billion by 2012xv. Contributions from unconventional markets in Latin America, Australia and the emerging markets in the Middle East and African Region and increased Abbreviated New Drug Applications (ANDAs) approvals in the US would lead the industry to shine in the upcoming days, SMEs will benefit from boosted contract production for western firms as gradually they would learn to comply the standards of the developed nations e.g. Dishman and GVK-Biosciences undertake contract research for western companies, Sun pharma manufacturing for Eli Lilly. Acquisition of foreign companies will lead to a strong increase in foreign production by Indian manufacturers, which will have a dampening effect on exports. SUMMARY The global state of affairs direct us to the fact that tackles the non-tariff measures namely the strict quality regulations to exports of pharma products in various countries and the lengthy documentation processes demanded by the importing country regulatory authorities etc. need to be addressed through consistent efforts and greater interaction with the concerned agencies of the choicest markets for the exporters. The Indian companies are putting their act together to tap the generic drugs markets in the regulated high margin

Page 9 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

markets of the developed countries. The US market remains to be the most lucrative market for the Indian companies led by its market size and the intensity of blockbuster drugs going off patent. Based on the retrospective data USA, Germany, Russia, UK, China, Brazil, Canada, South Africa, Nigeria, Netherlands, Spain, Turkey, Ukraine, Viet Nam, Israel, Italy, Mexico, UAE, Singapore, Iran had been potential importers of Indian Drugs. Countries like South Africa, Israel, Turkey, Kenya, Singapore, UK, China, Russia, Italy and Vietnam etc. have been identified to be potential prospective markets with high growth rates of imports from India. Africa, Latin America, ASEAN and CIS countries with huge demands deem them to be put in the category of focus countries as these are the emerging markets and have a huge potential with day in day out incremental growth rates of per capita drugs consumptions supported by treaties like SAFTA (with SAARC), treaties with GCC, EU, Japan, Korea etc. If India is able to take a 10% slice in the emerging market in developed countries it will open an opportunity of around $50bn at current prices of patented and branded drugs and shall be able to surpass the major exporters of the world.

Page 10 of 11

Indian Pharmaceutical Export Industry: Contemporary scenario, critical analysis and future trends.

REFERENCES i ii iii iv Foreign Trade Performance of India: Accessed on 30, Sep-2011: Economic Survey of India, 2010: Accessed on 30, Sep- 2011: Report of the Task Force on Pharmaceuticals (2009): Let all pharma M&As be cleared by CCI: Plan panel group: Accessed on 05, Oct-2011: v The introduction of Pharmaceutical patents in India- NBER Working Paper: vi vii viii Report of the Task Force on Pharmaceuticals- Feb 2009: Global Bilaterals data: Accessed on 26, Sep-2011: Third round up of Developments in Pharmaceuticals Sector, July 2009: ix x xi xii xiii xiv Report of the Task Force on Pharmaceuticals 25 February 2009: TRIPS: India - Patent Protection for Pharmaceuticals: Delayed demise of DEPB scheme: Accessed on 26, Sep-2011: Union Budget of India:: Accessed on 30, Sep- 2011: Report of the Task Force on Pharmaceuticals 25 February 2009: Mc Kinsey Report on Indian Pharma Industry 2015: xv Third round up of Developments in Pharmaceuticals Sector, July 2009:

Page 11 of 11

Sign up to vote on this title
UsefulNot useful

Master Your Semester with Scribd & The New York Times

Special offer for students: Only $4.99/month.

Master Your Semester with a Special Offer from Scribd & The New York Times

Cancel anytime.